Okura Risa, Yoshioka Haruna, Yoshioka Manabu, Hiromasa Kana, Nishio Daisuke, Nakamura Motonobu
Department of Dermatology, University of Occupational and Environmental Health, Kitakyushu, Japan.
Exp Dermatol. 2014 May;23(5):347-8. doi: 10.1111/exd.12402.
BRAF-activating somatic mutations often exist in malignant melanoma. The underlying molecular mechanism of somatic BRAF mutation inductions remained to be clear. Activation-induced cytidine deaminase (AID), a member of a cytidine deaminase family, and APOBEC3B induce somatic mutations and recently have been indicated to be involved in the pathomechanism of several kinds of cancers. The aim of this study was to explore the expression level of AID and APOBEC3B in BRAF-mutation- containing malignant melanoma. Immunohistochemical study demonstrated that 9 of 10 malignant melanomas with high AID expression had BRAF(V600E) mutation. Eight of them developed multiorgan metastases or multiple lymph node metastases afterwards. Although the size of the patient panel was small, the results indicate that there might be an association between AID expression and BRAF mutation in melanoma.
BRAF激活的体细胞突变常存在于恶性黑色素瘤中。体细胞BRAF突变诱导的潜在分子机制仍不清楚。激活诱导的胞嘧啶脱氨酶（AID）是胞嘧啶脱氨酶家族的一员，APOBEC3B可诱导体细胞突变，最近有研究表明它们参与了几种癌症的发病机制。本研究的目的是探讨AID和APOBEC3B在含有BRAF突变的恶性黑色素瘤中的表达水平。免疫组织化学研究表明，10例AID高表达的恶性黑色素瘤中有9例存在BRAF（V600E）突变。其中8例随后发生了多器官转移或多发淋巴结转移。尽管患者样本量较小，但结果表明黑色素瘤中AID表达与BRAF突变之间可能存在关联。
